Emergent inks anthrax combo vax deal with BARDA worth up to $1.6bn

By Staff Reporter

- Last updated on GMT

Related tags: Immune system

Emergent inks anthrax combo vax deal with BARDA worth up to $1.6bn
Emergent BioSolutions could make up to 52 million doses of its combination anthrax vaccine in a five-year supply deal with the US government potentially worth $1.6bn.

In an SEC filing Friday, the firm said it has signed a five-year procurement contract with the Biomedical Advanced Research and Development Authority (BARDA) which could net the firm as much as $1.6bn.

An initial $200m will cover the supply of two million doses of Emergent’s vaccine NuThrax (anthrax vaccine adsorbed with CPG 7909 adjuvant). However, the contract also includes procurement options for an additional 7.5 million to 50 million doses, valued from approximately $255 million to up to $1.4 billion.

"Emergent is pleased that BARDA has selected NuThrax to address the US government's desire for a next generation anthrax vaccine with an enhanced product profile that includes requiring fewer doses and eliciting a faster immune response,"​ said Daniel J. Abdun-Nabi, Emergent’s CEO.

"We look forward to collaborating with BARDA to further develop NuThrax towards an EUA-eligible product for the SNS and subsequently towards FDA licensure."

NuThrax is comprised of Emergent’s BioThrax (Anthrax Vaccine Adsorbed) combined with the oligodeoxynucleotide compound CPG 7909.

Since 2008 Emergent has been supporting the US Government’s programme to stockpile the product in anticipation of the need for mass vaccinations owing to a future bio-terrorist anthrax attack.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars